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Abstract Renal cysts are clinically and genetically heteroge-
neous conditions. Polycystic kidney disease (PKD) is com-
mon and its characterization has paved the way for the iden-
tification of a growing number of cilia-related disorders
(ciliopathies) of which most show cystic kidneys. While the
recessive form of PKD (ARPKD) virtually always presents in
childhood, early onset can, in some instances, also occur in the
dominant form (ADPKD). Both ADPKD genes (PKD1 and
PKD2) can also be inherited in a recessive way, making the
story more complex with evidence for a dosage-sensitive
network. Several phenocopies are known, and mutations in
HNF1ß or genes that typically cause other ciliopathies, such
as nephronophthisis, Bardet–Biedl, Joubert syndrome and
related disorders, can mimic PKD. An accurate genetic diag-
nosis is crucial for genetic counseling, prenatal diagnostics,
and the clinical management of patients and their families.
The increasing number of genes that have to be considered in
patients with cystic kidney disease is challenging to address
by conventional techniques and largely benefits from next-
generation sequencing-based approaches. The parallel analy-
sis of targeted genes considerably increases the detection rate,
allows for better interpretation of identified variants, and
avoids genetic misdiagnoses.
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Classification and differential diagnosis of cystic kidneys
In their seminal studies, Osathanondh and Potter systemati-
cally classified renal cystic diseases into four distinct types
[1]. Potter syndrome type I is referred to as autosomal reces-
sive polycystic kidney disease (ARPKD), type II as renal
cystic dysplasia, type III as autosomal dominant polycystic
kidney disease (ADPKD), and type IV occurs when a
longstanding obstruction in either the kidney or ureter leads
to cystic kidneys or hydronephrosis. Particularly types II–IV
can be part of many syndromes. While this classification still
has an impact for pathoanatomical descriptions, it is hardly to
be reconciled with clinical and genetic entities and, conse-
quently, it is more and more being replaced by the genetic
nomenclature.
An accurate diagnosis is essential to both the management
of patients with cystic kidneys and the counseling of their
families. When an effort is made to classify the wide array of
different entities with renal cysts, it might be helpful to first
distinguish between acquired and inherited forms. Knowledge
of the family history and the clinical picture, together with the
location and morphology of the cysts, and any possible
extrarenal manifestations should help the treating physician
in the decision-making process. In patients with additional
extrarenal features (in particular those with growth retardation,
learning difficulties, and/or microcephaly), cytogenetic or ar-
ray comparative genomic hybridization (array CGH) studies
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may be useful to exclude rearrangements or aberrations such
as large deletions or duplications.
Inherited cystic kidney disorders mainly include ADPKD
and ARPKD, glomerulocystic kidney disease, and entities
comprising the medullary cystic kidney disease–
nephronophthisis complex. Notably, cystic kidneys are an
important feature of numerous genetic syndromes, such as
the mainly recessively inherited ciliopathies Bardet–Biedl,
Joubert, Meckel, and Jeune syndromes or the dominant disor-
ders of tuberous sclerosis (TSC), von Hippel–Lindau (VHL)
disease, and branchio-oto-renal syndrome.
Polycystic kidney disease
More than 10 years ago, characterization of polycystic kid-
neys paved the way for the identification of a growing number
of cilia-related disorders. It is becoming increasingly evident
that most ciliopathies have a renal cystogenic component,
making kidney cyst formation a hallmark feature of
ciliopathies (Fig. 1) [2, 3]. ADPKD is the most frequent life-
threatening genetic disease, with a prevalence of 1/500–1,000
live births, affecting approximately 12.5 million individuals
worldwide [4]. About 5–10 % of adult patients who require
renal replacement therapy are affected by ADPKD that is
usually transmitted in an autosomal dominant fashion.
Clinical symptoms typically do not arise until adulthood;
however, there is striking phenotypic variability even within
the same family, indicating that modifying genes, epigenetic
mechanisms, and stochastic and/or environmental factors con-
siderably influence the clinical course in ADPKD. About 2 %
of ADPKD patients present with early clinical manifestations
before age 15 years [3]. Among these are cases with signifi-
cant perinatal morbidity and mortality sometimes indistin-
guishable from that due to severe ARPKD. ARPKD is much
rarer than its dominant counterpart and has a suspected inci-
dence of about 1 in 20,000 live births among Caucasians,
corresponding to a carrier frequency of approximately 1:70
in non-isolated populations. Isolated and inbred populations
may have considerably higher prevalences. For example,
Kaariainen and colleagues reported an incidence of 1:8,000
in Finland [5]. In contrast to ADPKD, ARPKD is typically an
infantile disease. Notably, among all children with PKD in
departments of pediatric nephrology, the total number of
patients with ARPKD equals the number of individuals af-
fected with early-onset ADPKD [3].
Autosomal recessive PKD
Although the clinical spectrum in ARPKD is much more
variable than generally presumed, and even only moderately
affected elderly people have been described [6, 7], the
majority of patients are severely affected and ARPKD is
identified late in pregnancy or at birth. Affected fetuses dis-
play a “Potter” oligohydramnios phenotype with massively
enlarged kidneys, pulmonary hypoplasia, a characteristic fa-
cies, and contracted limbs with club feet. Approximately 30–
50 % of affected neonates die shortly after birth from respira-
tory insufficiency due to pulmonary hypoplasia and thoracic
compression by the excessively enlarged kidneys (Fig. 2a–c).
Ultrasound scans typically show bilaterally enlarged
hyperechoic kidneys with poor corticomedullary differentia-
tion, retained reniform contour, and multiple tiny cysts con-
fined to distal tubules and collecting ducts (Fig. 2d–g;
Table 1). Macroscopically, the cut surface demonstrates corti-
cal extension of fusiform or cylindrical spaces arranged radi-
ally throughout the renal parenchyma from the medulla to the
cortex (Fig. 3a, b). Invariable histological manifestations are












Fig. 1 Schematic diagram of a primary cilium and associated processes.
Polycystic kidney disease (PKD) is controlled by a defined network of
different genes/proteins discussed in this review. Cilia are small antennae
that detect a variety of different extracellular stimuli and orchestrate
multiple signaling pathways with nuclear trafficking of some molecules
[e.g., C-termini of polycystin-1 (PC1 ) and fibrocystin/polyductin
(FPC)]. The inner ciliary structure is defined by the axoneme that is
composed of nine microtubule doublets derived from the basal body and
mother centriole of the centrosome. Along this microtubule core, the
transport of proteins in the anterograde direction toward the tip of the
cilium and in the retrograde direction towards the cell body is organized
by an elaborate process called intraflagellar transport
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lined by columnar or cuboidal epithelium that usually remain
in contact with the urinary system (unlike ADPKD), whereas
glomerular cysts (as in ADPKD) or dysplastic elements (e.g.,
cartilage; as in other ciliopathies such as Meckel syndrome)
are usually not evident in ARPKD kidneys (Fig. 3c, d).
However, during early fetal development, a transient phase
of proximal tubular cyst formation has been identified that is
largely absent by birth [8]. With advancing clinical course the
kidney structure might increasingly resemble the pattern ob-
served in ADPKD with renal cysts that vary considerably in
size and appearance, often also accompanied by some degree
of interstitial fibrosis [9].
Arterial hypertension, often difficult to control despite
multi-drug treatment, usually develops during the first months
of life and affects up to 80 % of children with ARPKD.
Careful blood pressure monitoring is essential to prevent
sequelae of hypertension (e.g. cardiac hypertrophy, congestive
heart failure), and deterioration of the renal function [7].
While the early appearance of ARPKD is typically clearly
dominated by renalmanifestations and associated co-morbidities,
histological liver involvement is present in everyARPKD patient
from early embryonic development on, as reflected by the disease
term “polycystic kidney and hepatic disease 1 (PKHD1).” These
obligatory liver changes are characterized by defective
remodeling of the ductal plate with congenital hepatic fibrosis
and biliary duct ectasia [10, 11], defined as ductal plate mal-
formation (DPM) (Fig. 3e) which is also a frequent feature in
other ciliopathies such as, for example, Bardet–Biedl, Joubert,
Meckel, and Jeune syndrome. Biliary anomalies may develop
at any stage of the physiological involution–remodeling pro-
cess, and the timing or stage of development determines the
resulting clinical and histological phenotype [12].
Apart from the portal tracts, the remaining liver parenchyma
in ARPKD usually develops normally and liver enzymes, except
for cholestasis parameters that might be elevated, are character-
istically not increased. The hepatobiliary complications may
dominate the clinical picture, particularly in older patients.
DPM leads to progressive hepatic fibrosis and consecutive portal
hypertension that causes hypersplenism with pancytopenia and
esophageal varices with upper gastrointestinal bleeding [7, 13].
Primary management of variceal bleeding includes endoscopic
approaches, such as sclerotherapy or variceal banding.
Occasionally, portosystemic shunting or liver–kidney transplan-
tation (sequential or combined) has to be considered. ARPKD
patients with liver cysts due to extensive dilatations of intra- and
extrahepatic bile ducts (Caroli’s disease and syndrome) are at
increased risk of recurrent episodes of ascending bacterial
cholangitis that may cause fulminant hepatic failure [14].
Although most patients show a comparable degree of se-
verity with regard to liver and kidney affection (renal–
hepatobiliary morbidity pattern, such as in a patient with renal
insufficiency, it is highly likely that also the liver is consider-
ably affected and vice versa), there is no direct correlation or
interdependency between those two organs. Single ARPKD
Fig. 2 a–h Autosomal recessive
polycystic kidney disease
(ARPKD). a Baby with distended
abdomen due to voluminous
kidneys that led to respiratory
problems and early demise. b
Abdominal situs of a perinatally
demised ARPKD patient with
symmetrically enlarged kidneys
that maintained their reniform
configuration. c Potter’s
phenotype with distinctive facial
features due to a lack of amniotic
fluid. d–h Renal ultrasound scans
of babies and young children with
ARPKD. Symmetrically enlarged
echogenic kidneys with fusiform
dilations of collecting ducts and
distal tubules are arranged
radially throughout the renal
parenchyma from medulla to
cortex
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patients may present with an organ-specific phenotype, i.e.,
either an (almost) exclusive renal phenotype or a predominant
or mere liver phenotype. In accordance with these observa-
tions, it has been demonstrated that PKHD1 mutations can
cause isolated congenital hepatic fibrosis or Caroli’s disease
[7, 15]. It is noteworthy that two transgenic mouse models for
Pkhd1 display an isolated liver phenotype without any renal
involvement [16].
To date, PKHD1 is the only known gene for classical
ARPKD, but there is compelling evidence for locus heteroge-
neity and phenocopies. Thus, single heterozygous mutations
and results that are merely based on linkage need to be
interpreted with caution. Patients with two truncating
mutations generally display a severe phenotype with peri- or
neonatal death, whereas patients surviving the neonatal period
usually carry at least one hypomorphic (missense) mutation.
Due to allelic heterogeneity and a high level of missense
mutations and private changes, mutation analysis for
PKHD1 is still laborious, but it has greatly benefited from
the availability of new sequencing techniques.
PKHD1 is a large gene that extends over a genomic seg-
ment of almost 500 kb on chromosome 6p12. The longest
open reading frame comprises 66 exons that encode
polyductin/fibrocystin, a type I single-pass transmembrane
protein of 4,074 amino acids [17, 18]. In common with both
ADPKD proteins (polycystin-1 and polycystin-2) and most
Table 1 Characteristics of autosomal recessive and autosomal dominant polycystic kidney disease
Characteristics ARPKD ADPKD
Synonyms Potter type I Potter type III
Incidence Approx. 1:20.000 1:500–1.000 (approx. 2 % early manifesting)
Pathology of kidneys
Macroscopy Massively, symmetrically enlarged kidneys (reniform) Generally enlarged (also reniform), but usually to a lesser
extent
Location of cysts Dilated collecting ducts and distal tubules Cysts in all parts of the nephron (including glomerulus)
Ultrasound and
diameter of cysts
At onset, typical pepper–salt pattern evident on ultrasound
scan, increased echogenicity of renal parenchyma
throughout cortex and medulla due to tiny, sometimes
invisible cysts (usually <2 mm); with advancing age, cysts
up to several centimeters large appear, similar to ADPKD
pattern
Cysts of different size in cortex and medulla (usually several
larger cysts in adults); at onset often small, however,
sometimes already several centimeters early in childhood
Pathology of liver Mandatory: ductal plate malformation/congenital hepatic
fibrosis with hyperplastic biliary ducts and portal fibrosis
(may impress as Caroli disease)
“Liver cysts” common in adults, but rare in children.
Occasionally, ductal plate malformation/congenital
hepatic fibrosis
Associated anomalies Rarely pancreatic cysts and/or fibrosis; single case reports
with intracranial aneurysms
Pancreatic cysts and/or cysts in other epithelial organs;
intracranial aneurysms in approx. 8 %, familial clustering
Main clinical
manifestations
Peri-/neonatal period: respiratory distress (30–50 % of cases) General onset 3rd–5th decade with arterial hypertension,
proteinuria, hematuria, and/or renal insufficiency; approx.
2 % early manifestation in childhood (rarely with perinatal
respiratory distress)
With prolonged survival, renal insufficiency, portal
hypertension, and other variable co-morbidities
Risk for siblings 25 % 50 % (except for rare cases of spontaneous mutation with
virtually no risk)
Risk for own children <1 % (unless unaffected parent is related to his/her affected
partner, or ARPKD is known in the unaffected partner’s
family)
50 % (also for patients with a spontaneous mutation)
Manifestation in affected
family members
Often similar clinical course in siblings (however, in approx.
20 % extensive intrafamilial variability)
Variable, however, often similar within the same family; in
the case of early manifestation approx. 50 % recurrence
risk
Parental kidneys No alterations Except for cases of spontaneous mutation, usually one parent
is affected and shows renal cysts (be careful when parents
are too young for definite clinical diagnosis, namely, <30–
40 years)
Prognosis In perinatal cases with respiratory distress, usually poor; for
those surviving the neonatal period, much better with renal
death in approx. 15–30 % in childhood/early adolescence,
often severe complications (e. g., esophageal varices) due
to portal hypertension; if possible transplantation (often
combined kidney–liver TX)
In early manifesting cases, often better than in ARPKD. In
“adult” cases, chronic renal failure in approx. 50 % by age
of 60 years; median age of ESRD onset (58.1 vs.
79.9 years in PKD1 vs. PKD2)
ARPKD, Autosomal recessive polycystic kidney disease; ADPKD, autosomal dominant polycystic kidney disease; ESRD, end stage renal disease; TX,
transplant
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other cystoproteins, fibrocystin is localized to primary cilia
with the highest concentration in the basal body area [19].
This striking pattern of subcellular localization and known
interactions with, for example, polycystin-2, place fibrocystin
at key sites of microtubule organization. In line with its
proposed role as a ciliary-localized membrane protein, an
18-residue motif in the cytoplasmic tail of fibrocystin serves
as a ciliary targeting signal [20].
Autosomal dominant PKD
The majority of ADPKD patients (approx. 80–85 %) carry a
germline mutation in the PKD1 gene on chromosome 16p13,
whereas about 15–20 % harbor a mutation in the PKD2 gene
on chromosome 4q21 [4]. As in PKHD1 , there is also a high
level of allelic heterogeneity in both ADPKD genes with most
mutations being private. About 70 % of all PKD1 mutations
and even more than 80 % of all PKD2 mutations currently
listed in the ADPKD mutation database are predicted to be of
a protein truncating character.
The encoded proteins polycystin-1 and polycystin-2 are
both glycosylated integral membrane proteins that interact
via their C-terminal coiled–coil domains. Polycystin-2 is a
member of the transient receptor potential (TRP) protein
superfamily and known to function as a divalent cation chan-
nel that is particularly involved in cellular Ca2+ signaling [21].
While the definite roles of polycystin-1 and the ARPKD
protein fibrocystin are still speculative, there is increasing
evidence from mutational and functional data that fibrocystin
is part of the polycystin complex [22–25].
PKD1 sequencing is complicated by the presence of six
pseudogenes in a duplicated region adjacent to the original
PKD1 locus. It is still a matter of debate if these pseudogenes
are merely “junk” or functional DNA. Several lines of evi-
dence show that some pseudogenes are “alive”with functional
roles in gene expression and regulation, such as by acting as
microRNA decoys [26]. Mutation analysis in ADPKD has
much improved during recent years, and it is now generally
possible to detect the disease-causing mutation in most affect-
ed families. Sequencing of the large and structurally complex
PKD1 gene is usually the first step; if negative, it is followed
by PKD2 sequencing and finally MLPA (multiplex ligation-
dependent probe amplification) analysis of both genes to
detect larger deletions.
While clinical symptoms usually only arise in adulthood,
there is considerable phenotypic variability even within the
same family, and in about 2 % of ADPKD patients the
symptoms become manifest during childhood. Notably, af-
fected families with early-manifesting offspring have a high
recurrence risk for the birth of a another child with similar
clinical manifestations. This important piece of information
should be shared with afflicted families and clearly hints at a
common familial modifying background for early and severe
disease expression [27]. Early disease manifestation in
ADPKD is the most important differential diagnosis of
ARPKD. Parental renal ultrasound is a must and should be
performed in every child with cystic kidney disease of un-
known origin. However, the family history does not need to be
positive because some alleles are incompletely penetrant
(hypomorphic), and approximately 2–5 % of all mutations in
ADPKD are thought to arise de novo. Moreover, both
ADPKD genes can also be inherited in a recessive way [3].
Fig. 3 a–f Microscopic and macroscopic appearance of autosomal
recessive polycystic kidney disease (ARPKD). a Considerably enlarged
kidney with retained reniform configuration (patient passed away at the
age of 2.5 months). b , c Cross sections of ARPKD kidneys reveal
cortical extension of fusiform or cylindrical spaces arranged radially
throughout the renal parenchyma from medulla to cortex. d , e
Microscopic appearance of fusiform dilations of renal collecting ducts
and distal tubuli lined by columnar or cuboidal epithelium. These dilated
collecting ducts run perpendicular to the renal capsule. f Obligatory
hepatobiliary changes in ARPKD subsumed as ductal plate malformation
and characterized by dysgenesis of the hepatic portal triad with hyper-
plastic biliary ducts and congenital hepatic fibrosis
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Diagnosis of ADPKD by ultrasound is established in at-
risk individuals aged 15–39 years if three or more (unilateral
or bilateral) renal cysts are detected. About 60 % of children
aged <5 years, and 75–80 % of children aged 5–18 years with
a known PKD1 mutation had renal cysts detectable by ultra-
sound. In general, the finding of even one renal cyst should
alert a pediatrician to the possibility of ADPKD because
simple cysts are otherwise extremely rare in childhood. In
children with a 50 % risk of ADPKD, the finding of one cyst
can thus be considered diagnostic [28]. Renal cysts can vary
considerably in size and appearance arising from all segments
of the nephron (Figs. 4, 5), and they usually show progressive
enlargement and may become disconnected from the tubular
space (Fig. 5). The Consortium for Radiologic Imaging for the
Study of Polycystic Kidney Disease (CRISP) recently showed
that renal enlargement in ADPKD mimicked exponential
growth. Over a 3-year period among more than 200 patients,
the renal volume increased by a mean of 63.4 ml (5.3 %) per
year as a result of the expansion of cysts in a continuous
process associated with the decline of renal function. While
this leads to progressive destruction of the adjacent renal
parenchyma and massive enlargement of the kidneys, renal
function can be preserved for a long time as functioning
nephrons undergo compensatory hypertrophy [29]. Chronic
renal failure presents in about 50 % of patients by the age of
60 years. PKD2 is usually significantly milder than PKD1,
with the development of end-stage renal disease (ESRD) at a
later age and a lower prevalence of arterial hypertension and
urinary tract infections. Patients with PKD1 develop ESRD
approximately 20 years earlier than those with PKD2, with a
median age of onset of ESRD of 58.1 years and 79.9 years,
respectively. The greater severity of PKD1 is due to the
development of more cysts at an early age—not to faster cyst
growth [30]. A recent study on more than 500 pedigrees with
ADPKD has provided important information and demonstrat-
ed that the type of PKD1 mutation significantly correlates
with renal survival [31]. In that study, patients with a non-
truncating mutation exhibited ESRD 12 years later than those
with a truncating mutation in the same gene (67.9 vs.
55.6 years).
While the kidneys are the main organ involved, ADPKD is
clearly a systemic disorder with profound extrarenal disease
burden. Polycystic liver disease is by far the most common
extrarenal manifestation in ADPKD and is usually a benign
disease that may cause mechanical compression or irritation.
Notably, polycystic liver disease can also occur in isolation as
an autosomal dominant trait with a mutation in either
PRKCSH or SEC63 encoding non-ciliary proteins with roles
in protein translocation, folding, and quality control in the
endoplasmic reticulum. All PKD genes are transmembrane
proteins passing through the translocation and quality control
machinery in the ER. Thus, PKD and PLD overlap not only
clinically but also genetically and functionally, with evidence
for a dosage-sensitive network [32]. Liver cysts affect about
75 % of ADPKD patients in their sixties [33] and usually gain
in size and number as they do in the kidney. Women, especially
those who have used hormones and/or have had multiple preg-
nancies, are more often and more severely affected, suggesting
that estrogen influences hepatic cyst growth. Estrogen is known
to stimulate the proliferation of cholangiocytes, and estrogen
receptors are expressed in epithelial cells lining hepatic cysts.
Cysts in other epithelial organs (e.g., seminal vesicles, pancreas,
Fig. 4 Typical sonographic images of autosomal dominant polycystic kidney disease (ADPKD) in different patients of adolescent age
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arachnoid membrane) and diverticulosis are also common.
Among the cardiovascular co-morbidities, intracerebral aneu-
rysms play a significant role and are present in about 8 % of
ADPKD patients. The prevalence is even higher in patients with
a positive family history for intracerebral aneurysms and/or
subarachnoid hemorrhage. Cardiac valve disease, particularly
mitral valve prolapse, can be diagnosed in approximately 25 %
of patients with ADPKD.
“Neoplasia in disguise”: cystogenesis shows similarities
to tumorigenesis, but patients usually do not develop
carcinoma
Although benign, the cystogenic process in PKD created by
the sustained proliferation of epithelial cells resembles
profiles often observed in tumors. Thus, some call
ADPKD “neoplasia in disguise” [34, 35]. Many pro-
cesses defective in ciliopathies, such as epithelial and
planar cell polarity, play crucial roles in tumorigenesis
[36]. Cilia are directly involved in cell cycle regulation
and the coordination of cancer-related signaling mole-
cules [37, 38]. Fortunately, however, renal cell carcino-
ma or any other tumor only rarely develops in PKD
despite the frequency of hyperplastic polyps and micro-
scopic adenomas in which aneuploid karyotypes with
chromosomal extra-copies can often be determined.
This phenomenon in cell growth and tumorigenesis is
explained by the so-called aneuploidy paradox, which
means that chromosome gains cause a proliferative dis-
advantage rather than advantage, as one may have as-
sumed [39]. The integrity of cilia and the polycystin complex
are required for the maintenance of mitotic spindle orientation
and centrosome amplification [40, 41]. Interventions targeted
at cell cycle regulation may thus be another smart drug ap-
proach, as demonstrated by beneficial effects of the cyclin-
dependent kinase inhibitor roscovitine on cystic kidney dis-
ease in two PKD mouse models [42].
ADPKD exhibits some similarities to hereditary can-
cer syndromes, such as von Hippel-Lindau (VHL) syn-
drome and tuberous sclerosis (TSC). VHL is an autoso-
mal dominant condition with a prevalence of about
1:30,000–40,000 caused by inactivating mutations of
the VHL tumor suppressor gene and characterized by
the development of hemangioblastomas in the brain,
spinal cord, and retina often combined with renal clear
cell carcinoma and pheochromocytoma [43]. Patients
with VHL are also at increased risk for epididymal
cystadenomas and cysts in the kidney and pancreas.
TSC is caused by an autosomal dominant germline
mutation in either TSC1 or TSC2 and can affect a
broad range of organs with a birth incidence of approx-
imately 1:6,000 [44]. About 90 % of patients experience
often intractable seizures and approximately one in two
patients shows cognitive impairment, autism, or other
behavioral disorders. Renal manifestations are the lead-
ing cause of death in adult patients with TSC [45];
cystic kidney disease occurs in 50 % of TSC patients,
and angiomyolipomas are diagnosed in 80 %. Many
Fig. 5 a , c Macroscopic appearance of advanced-stage autosomal dom-
inant polycystic kidney disease (ADPKD) showing enlarged kidneys
with multiple cysts that almost completely destroyed and replaced the
renal parenchyma. b On cut section, multiple cysts in the cortex and
medulla can be seen that vary considerably in size and appearance, from a
few millimeters to diameters of many centimeters
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other parts of the body (e.g., heart and brain) can also
be affected by primarily non-cancerous tumors. A third
of all female patients display pulmonary involvement,
specifically lymphangioleiomyomatosis. Frequent skin mani-
festations in TSC are white spots, facial angiofibromas, and
peri-/subungual fibromas.
Both TSC and VHL intersect with the primary cilium and
the mTOR signaling network known to be upregulated in
PKD and several tumor types [46]. The activity of mTOR is
downregulated by polycystin-1 and the TSC1/TSC2 tumor
suppressor complex, ultimately resulting in G1-cell cycle
arrest and apoptosis. A synergistic role of polycystin-1 and
the TSC2 gene product tuberin has been suggested in the more
severe and earlier onset PKD phenotype in individuals har-
boring a deletion encompassing the adjacent TSC2 and PKD1
genes on chromosome 16p13 compared to those with a PKD1
mutation alone. Amolecular explanationmight be the fact that
both proteins interact and tuberin traffics polycystin-1 to the
plasma membrane [47].
PKD phenocopies
Hepatocyte nuclear factor 1ß-related disease
Autosomal recessive PKD and ADPKD can be mimicked by
mutations in a couple of other genes (Fig. 6). The transcription
factor hepatocyte nuclear factor 1ß (HNF1ß) (HNF1ß/TCF2
gene) plays a critical role in the diagnostics of cystic kidney
disease. In line with a broad expression pattern from early
embryonic development onwards, mutations in this transcrip-
tion factor can result in a multitude of various phenotypes
summarized as renal cyst and diabetes syndrome.
HNF1ß mutations follow an autosomal dominant mode of
inheritance. However, as true for many transcription factors,
incomplete penetrance, considerable variable expressivity,
and a high fraction of spontaneous mutations have to be kept
in mind when the family history is evaluated. Spontaneous de
novo mutations are found in about 30–50 % of all HNF1ß
patients. Almost half of all HNF1ß mutations are large dele-
tions that usually encompass about 1.4 Mb of genomic DNA
on 17q12, includingHNF1ß and 14 other genes. In contrast to
the deletion, the reciprocal duplication due to non-allelic
homologous recombination in 17q12 is rare. Surprisingly,
most patients carrying the microdeletion do not show a more
severe phenotype than patients harboring an HNF1ß point
mutation. However, there is now convincing evidence that a
few of those patients with a large genomic rearrangement in
17q12 may have cognitive impairment, seizures, and other
neurodevelopmental disorders (e.g., schizophrenia and autism
spectrum disorders) [48, 49].
The most common renal phenotype thatHNF1ß mutations
lead to is cystic kidney dysplasia due to early embryonic
maldevelopment (Potter type II—more often type IIa with
enlarged kidneys than type IIb with renal hypodysplasia). In
cystic dysplasia, both kidneys usually lose their reniform
character (Fig. 7). The ultrasonographic pattern is irregular
with excessive connective tissue in between various sizes and
locations of cysts. Other features besides cystic kidneys and
maturity-onset diabetes that are quite common in HNF1ß
patients are genital tract abnormalities, hyperuricemia, in-
creased liver enzymes, hypomagnesemia, and pancreatic atro-
phy with endocrine and exocrine insufficiency.
Clinical variability associated with HNF1ß mutations is
extensive and not well understood to date. Phenotypes may
range from prenatal manifestations to very mild symptoms in
elderly family members. Renal phenotypes may even vary in
the same patient, with cystic dysplasia (later renal "agenesis")
in one kidney and a polycystic disease pattern in the other
kidney (own unpublished data). Overall, HNF1ß mutations
are thought to constitute the main cause of prenatally diag-
nosed bilateral hyperechogenic kidneys [50]. While many of
these fetuses display normal-sized kidneys often with bilateral
cortical cysts and normal amniotic fluid volume, HNF1ß
patients may also show Potter’s sequence with oligo-/
anhydramnios and massively enlarged polycystic kidneys
(>+3 standard deviations) that mimic ARPKD. In accordance
with these observations, mice with an Hnf1ß mutation were
found to show a PKD-like phenotype with diminished Pkhd1
expression [51]. HNF1ß is a master regulator with a major
effect on many cystic kidney disease genes, such as PKHD1 ,
PKD2 , andUMOD , and there is evidence for a transcriptional
network in PKDwhich is a plausible explanation of why some
patients may resemble ARPKD or ADPKD patients.
There is also some evidence in the literature suggesting that
HNF1ß may serve as a tumor suppressor. After identifying a
50-year-old patient with ovarian and chromophobe renal cell
carcinoma, Rebouissou et al. found biallelic HNF1ß inactiva-
tion (by the combination of anHNF1ß germline mutation and
Fig. 6 Several phenocopies of polycystic kidney disease (PKD) are
known and mutations in the transcription factor hepatocyte nuclear factor
1 beta (HNF1ß) or genes that typically cause other ciliopathies, such as
nephronophthisis (NPHP), Bardet-Biedl (BBS), and Joubert syndrome
and related disorders (JSRD), can mimic PKD in some cases
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a somatic gene deletion) in two of 12 chromophobe renal cell
carcinomas [52]. Notably, the closely related homeodomain-
containing transcription factor HNF1α, to which HNF1ß
binds DNA as homo-dimers or hetero-dimers to activate tran-
scription of targeted genes, exhibits a well-established tumor
suppressor function in hepatocarcinogenesis and may also
participate in the development of other tumors, such as colo-
rectal and clear cell renal carcinomas. Recent data also suggest
a broader role and association of HNF1ß with other tumors,
such as ovarian and prostate cancer [53–55]. While it would
be clearly overpowered to stoke fears about significant cancer
risks in children carrying an HNF1ß germline mutation, it
might be reasonable to provide adult mutation carriers with
this information and discuss which standard investigations
would be appropriate in each individual case (due to the
absence of any official disease surveillance program).
Certain types of nephronophthisis
Nephronophthisis (NPHP) comprises a clinically and geneti-
cally heterogeneous group of autosomal recessive
tubulointerstitial cystic kidney disorders. Characterization of
NPHP proteins (nephrocystins) has considerably supported the
understanding of processes involved in cystogenesis and cilia-
related disorders. NPHP represents the most frequent genetic
cause of ESRD in children and young adults and typically
initially presents with a urinary concentrating defect [56, 57].
The most common form, juvenile NPHP, usually starts during
the first decade of life with manifestations of polyuria, poly-
dipsia, and anemia. Patients usually do not show arterial hy-
pertension before the onset of renal failure. The ultrasound
scans of NPHP patients generally show normal or small-sized
kidneys with increased echogenicity and often also the loss of
corticomedullary differentiation (Fig. 8). Cysts usually only
occur as secondary manifestations after patients have
progressed to end-stage renal failure and are typically located
at the corticomedullary junction. Histologically, tubular
basement membrane disintegration and thickening, tubular
atrophy, and disproportionate tubulointerstitial fibrosis with
minimal inflammation are observed [58] (Fig. 9).
Medullary cystic kidney disease (MCKD) is often regarded as
the autosomal dominant counterpart of NPHP (NPHP–MCKD
complex) with a usually later onset of renal failure than the
recessive forms. The ciliary protein uromodulin (= Tamm–
Horsfall glycoprotein), the most abundant protein in the urine
of healthy individuals, plays a major role and is encoded by
UMOD on chromosome 16p12 [59]. Mutations in this gene can
lead to different tubulointerstitial nephropathies, including
MCKD2, glomerulocystic kidney disease, and familial juvenile
hyperuricemic nephropathy, which may also be caused by mu-
tations in TCF2 (HNF1ß) and REN (renin). Only recently has
MUC1 , a locusmappedmore than a decade ago on chromosome
1q22, been identified as the gene underlying MCKD1 [60].
To date, about 20 genes have been described for recessive
NPHP, plus XPNPEP3 in which mutations cause an NPHP-
like phenotype (NPHP1L). Given that these genes only ac-
count for about one-half of all NPHP cases, further heteroge-
neity can be expected. NPHP1 on chromosome 2q13 is the
most commonly mutated gene in NPHP. In large series of
patients, a homozygous deletion of NPHP1 was present in
20–40% of cases [56, 57]; heterozygous deletions were found
in another 6 % of patients, harboring a concomitant point
mutation on the other parental NPHP1 allele [57]. Other
NPHP genes described to date may only contribute a minor
part to the total mutational load of typical NPHP.
It is important to note that many NPHP genes are pleiotro-
pic and can cause a much broader phenotypic spectrum (with
other ciliopathies such as Senior–Loken, Joubert, Meckel,
Ivemark, and Jeune syndrome) than just isolated NPHP.
Mutations in a subset ofNPHP genes can resemble PKDwith
enlarged kidneys and sometimes even prenatal manifestation
of Potter’s sequence. Obviously, these respective NPHPmem-
bers engage in a closely assembled protein–protein interaction
sub-network (Fig. 1). We recently identified ANKS6 as an
Fig. 7 a Cystic kidney dysplasia
due to early embryonic
maldevelopment (Potter type II).
Both kidneys have lost their
reniform structure. The histologic
(b) and ultrasonographic (c–f)
pattern is irregular, with excessive
connective tissue in between cysts
of various sizes and at different
locations
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additional member and the central component of this novel
cystoprotein module that connects NEK8 (NPHP9) to INVS
(NPHP2) and NPHP3 [61]. Some preliminary evidence con-
nects this module to oxygen-dependent hydroxylation and
mitochondrial function.
Other ciliopathies
In rare instances, PKD may be mimicked by mutations in
genes that typically cause other, usually complex ciliopathies,
such as Bardet–Biedl, Joubert and Meckel syndrome.
Fig. 8 a–f Sonographic appearance of patients of different ages with
nephronophthisis (NPHP). All patients show a typical NPHP pattern with
normal or small-sized kidneys, enhanced echogenicity of the renal cortex,
and reduced cortico-medullary differentiation (progressive with renal
failure); cysts (e.g., patient in c ) are usually a late sign and occur
secondarily after patients have progressed to end-stage renal disease and
are typically located at the cortico-medullary junction. a , b 10-year-old
boy with homozygous NPHP1 deletion, serum creatinine of 3 mg/dl,
glomerular filtration rate of 20ml/min andmild arterial hypertension. c , d
10- and 15-year-old patients with progressed clinical course. e 14-year-
old boy with Senior–Loken syndrome carrying a homozygous deletion of
the NPHP1 gene. Peritoneal dialysis was started recently. f 2-day-old







Fig. 9 a–d Renal histology of a 14-year-old female with juvenile NPHP
carrying a homozygous NPHP1 deletion. Chronic tubulo-interstitial al-
terations with tubular basement membrane disintegration and thickening,
focal tubular atrophy (arrow in d), cystic dilated tubuli (asterisk in b and
c), and disproportionate tubulo-interstitial fibrosis with some inflamma-
tory cells were observed
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Bardet–Biedl syndrome (BBS) is characterized by obesity,
hypogonadism, retinal degeneration, polydactyly, mental re-
tardation, and renal malformations. Various additional fea-
tures, such as hearing loss, diabetes mellitus, and other meta-
bolic defects, have also been described. Renal disease is a
major cause of morbidity and mortality in BBS and can be
very heterogeneous in phenotype. While some kidneys man-
ifest as NPHP with tubulointerstitial disease, others may ex-
hibit findings resembling those usually seen in ARPKD and
ADPKD patients, with enlarged, hyperechogenic kidneys and
loss of cortico-medullary differentiation, with or without
macrocysts. Currently, a total of 18 BBS genes and ALMS1
as the gene for the closely overlapping Alstrom syndrome
have been identified.
Meckel syndrome (MKS) is allelic to Joubert syndrome
(JS/JBTS) and related disorders (JSRD) and is positioned at
the severe end of the broad phenotypic spectrum of
ciliopathies [62]. These multisystemic disorders are of an
early developmental rather than degenerative nature.
Clinically and genetically they are heterogeneous with more
than 20 genes known to date. Classic disease manifestations in
patients withMKS comprise occipital meningoencephalocele,
cystic kidney dysplasia, hepatobiliary DPM, and postaxial
polydactyly. Several other features, such as shortening and
bowing of long tubular bones, heart defects, microphthalmia,
and cleft lip/palate, have been reported. Survival beyond birth
or the neonatal period is unusual, with the vast majority of
babies dying in utero. Prognosis in patients with JS/JBTS
varies considerably and largely depends on the extent and
severity of organ involvement. The clinical hallmark is
the so-called “molar tooth sign”, a complex mid-
hindbrain malformation with cerebellar vermis hypopla-
sia visible on magnetic resonance imaging. The clinical cor-
relates are developmental delay/mental retardation, neonatal
irregular breathing, hypotonia, ataxia, and eye movement
abnormalities [63]. Non-neurological features include poly-
dactyly, retinal dystrophy, hepatic fibrosis, NPHP, and other
cystic kidney disease phenotypes. In neonates and young
infants, particular attention should be paid to respiratory and
feeding problems.
Why is it important to know the underlying genetic
defect?
Although the clinical management of cystic kidney diseases of
different origin is practically the same (until effective drugs
are established), it is of major interest to know about the
underlying genetic defect for the different reasons that are
outlined below.
An often underestimated issue is the impact that a genetic
diagnosis may have onmany patients and their parents, i.e. the
relevance of finally being able to give the disease a name.
Information on the genotype is also clearly of major
importance when selecting patients for clinical trials and
for future treatments. For example, patients carrying
hypomorphic PKD1/PKD2 alleles can be expected to
progress slowly and may never develop ESRD; as such,
the benefits may not outweigh the risks of any new
treatment.
Knowledge of genotype improves clinical management
It is always good to know your “enemy” in detail and what
you are dealing with. Clinicians may find it helpful to have a
better understanding of the specific condition they are treating
and if there is any substantial risk for extrarenal disease
manifestation that might benefit from early detection and
disease monitoring ideally embedded in a multidisciplinary
approach.
For example, despite all similarities, ARPKD and ADPKD
are different diseases with different complications—and the
clinician should take this into account. While in children with
ARPKD portal hypertension is an invariable threat, ADPKD
patients are only very rarely affected by DPM and congenital
hepatic fibrosis. In contrast to ARPKD, cardiovascular co-
morbidities, in particular intracerebral aneurysms (ICAs), play
a significant role in ADPKD. An overall prevalence of asymp-
tomatic ICAs of about 8 % has been estimated for ADPKD
patients, with prevalence increasing with age, being about
23 % among the 60- to 69-year-old ADPKD patients in one
study [64]. General recommendations do not exist, and the
question of screening for ICAs in patients known to be affect-
ed with ADPKD is still a matter of debate and challenging in
each individual case. Recent data support very selective
screening for unruptured ICAs; widespread screening is def-
initely not indicated. Nevertheless, for both the patient and
treating physician, it might be good to know about the in-
creased risk in ADPKD, especially in patients with a positive
family history who have a doubled relative risk [64, 65].
Fortunately, among children and adolescents, aneurysm rup-
ture is very uncommon. Thus, screening might only be con-
sidered at the age of 20 years, especially when there is a
positive family history.
Mutations in NPHP genes and other members of the
ciliopathy spectrum may often lead to retinitis pigmentosa.
Although there is currently no cure for this condition, an early
diagnosis might help families cope better with the ultimate
progression of the disease and choose the right course. It is
widely accepted that the early learning of Braille correlates
strongly with both academic and employment success later in
life. Conversely, parents and patients can be reassured that
visual impairment is not part of the disease spectrum if, for
example, mutations in HNF1ß or any of the PKD genes have
been identified.
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Another good example is Alstrom syndrome which over-
laps with BBS and typically shows retinal dystrophy, obesity,
and endocrinological features. However, in contrast to BBS,
most patients with Alstrom syndrome have normal intelli-
gence and do not show polydactyly; they usually develop
more severe sensorineural deafness and early-onset type 2
diabetes mellitus. Other features important for proper clinical
surveillance are progressive pulmonary, hepatic and renal
failure, and different cardiac manifestations. More than half
of all Alstrom patients develop cardiac failure as a result of
dilated or restrictive cardiomyopathy.
In some cases, a genetic diagnosis ends an often lengthy
odyssey for the patients and families or may help to avoid
invasive procedures (e.g., kidney or liver biopsy).
Genetic counseling
It is only possible to discuss various aspects of diseases, such
as clinical course, disease spectrum, and recurrence risk, in
greater detail if the nature of the patient’s genotype is known.
Understandably, for parents who already have an affected
child and who wish to have more children, knowing whether
they carry a 50 % (as for autosomal dominantly inherited
disorders), 25 % (as for recessive diseases), or practically no
risk of recurrence has a huge effect on their decisions. The
term “practically no risk of recurrence” holds true when the
mutation in the patient arose de novo. A 100 % guarantee
cannot be given because of theoretically possible germline
mosaicism in one of the parents; thus, the use of “practically
no recurrence risk”. Autosomal dominant de novo mutations
are present in about 30–50 % of all HNF1ß patients. These
may also occur, in other dominant disorders, such as ADPKD,
but usually with a much less frequency (in up to 5 % of
ADPKD patients). The patients themselves harboring such a
de novo mutation carry a 50 % recurrence risk for their
own children; however, for parents and their families the
elucidation of a de novo event in the pedigree’s index
patient is a big relief.
A clear genetic diagnosis is also of interest to the rest of the
family in X-linked disorders. A frequent scenario for genetic
counseling is the healthy sister of an affected patient who is
afraid that her brother bears an X-linked mutation and that she
might be a carrier with a substantial disease risk for her own
children (then 50 % for boys).
With improved clinical management even patients with
early disease manifestation often reach adulthood and may
wish to have their own children. For these patients, it is of
major importance to know if they are afflicted by a recessive
or a dominant disease. While a dominant disease type will
mean a 50 % recurrence risk, recessive inheritance usually
results in a <1 % risk for offspring unless consanguineous
marriage takes place, the partner is equally affected, or a
patient of the same disease is present in the partner’s pedigree.
In particular, for male patients it might also be of interest to
distinguish between autosomal and X-linked inheritance, as a
father affected by anX-linked disorder can never have affected
sons.
Prenatal diagnosis
Many parents of children with ARPKD and other cystic
kidney diseases seek early and reliable prenatal diagnosis
to guide future family planning. The main reasons cited
for prenatal studies are the usually significant risk of
recurrence, frequently devastating early manifestations of
the disease, and often comparable clinical courses among
affected siblings.
An early and reliable prenatal diagnosis in “at risk”
families is usually only feasible by molecular genetic
analysis. For ARPKD, the dilemma with non-invasive
prenatal imaging techniques is that patients are typically
identified by ultrasound only late in pregnancy or even
only at birth. Even with state-of-the-art technology,
fetal sonography at the time when termination of preg-
nancy is usually performed frequently fails to detect
enlargement and increased echogenicity of kidneys or
oligohydramnios. In the past, indirect haplotype-based
linkage analysis has often been performed for ARPKD
in terms of prenatal diagnosis. However, due to the
aforementioned reasons with phenocopies and evidence
for further heterogeneity in ARPKD, haplotype-based
prenatal diagnostics is no longer state of the art and
regarded as too risky without knowledge of PKHD1
mutational status. It should only be performed in those
families in which the diagnosis has been previously
proven unequivocally. Still, molecular prenatal diagnos-
tics is usually done after chorionic villus sampling, an
invasive procedure undertaken quite late in the pregnan-
cy (no earlier than the 10–12th week of gestation).
Interested families should also be informed of the possi-
bility of pre-implantation genetic diagnosis at some sin-
gle diagnostic centers and that this procedure always
requires a high degree of coordination and work-up in
advance. A future scenario might be non-invasive prena-
tal testing of the fetal genotype by screening a maternal
blood sample.
Conclusions
We have learned during recent years that there is huge clinical
and genetic variability in cystic and polycystic kidney disease
even within the same family. Classical Mendelian inheritance
patterns with single-locus allelism may sometimes appear to
be insufficient to explain such phenomena as variable expres-
sivity and incomplete penetrance. It is rather likely that
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stochastic, epigenetic, and environmental factors modify the
phenotype. Furthermore, oligogenic inheritance with varia-
tions across multiple sites may further influence the clinical
outcome in some individuals [2]. Such “additional” alleles, the
so-called second-site modifiers, may exert an aggravating
effect in an epistatic manner and contribute to early and severe
disease expression in some patients. In these patients it is
hypothesized that the reduced dosage of disease proteins
(“dosage-sensitive network”) may disturb converging path-
ways, network integrity, and cell homeostasis, which may
ultimately explain the more severe clinical course [66, 67].
Further research is on-going and will hopefully provide data
on which firm conclusions can be drawn.
Next-generation sequencing (NGS) provides a rapidly
growing insight in these challenging issues and has revolu-
tionized genetic diagnostics. Conventional (Sanger) sequenc-
ing facilities are expensive with limited capacities and only
allow for a stepwise approach dependent onmutation frequen-
cies and the ethnic origin and phenotype of the patient. In the
case of parental consanguinity and in multiplex pedigrees with
more than one affected child, linkage analysis with subsequent
gene sequencing in the case of compatible haplotypes might
be an option. However, ultimately, all of these conventional
approaches are usually more cost- and time-intensive than
(targeted) NGS-based approaches that allow large-scale par-
allel sequencing of all disease genes that may have to be
discussed in a patient. Given overlapping disease phenotypes
and extensive allelism, usually multiple, often dozens, genes
have to be considered to be disease-relevant. Notably, NGS is
not NGS, and approaches are definitely not the same. More
than most other in vitro diagnostic tests, NGS needs strict
consideration of certain quality criteria. However, if all this is
warranted, NGS does not only improve the throughput, but
also the quality of genetic diagnostics. For example, in con-
trast to Sanger sequencing, by using NGS it is possible to
detect mosaicism and copy-number variations. For most
genes, large deletions/duplications make up about 5–10 % of
the total mutational spectrum of the respective gene, and for
some genes (e.g., in HNF1ß, almost 50 % of patients have
large deletions) the proportion is even much higher. Overall,
parallel analysis of all targeted disease genes allows for a
better interpretation of identified variants and avoids genetic
misdiagnoses. Such a targeted NGS-based approach consid-
erably increases the detection rate, allowing the major disease
gene to be clearly identified in the great majority of cases. In
terms of diagnostics, specific NGS panels, which ideally
should have a critical minimal size (i.e., comprising a suffi-
cient number of targeted genes), are thought to be currently
better than exome sequencing in the first place. However,
families who are analyzed by an NGS panel, but for whom
the mutations in known genes were not identified, should be
offered exome sequencing, which is already provided on a
diagnostic basis by some laboratories. Importantly, a
much more detailed form of informed consent is re-
quired for exome sequencing.
Genetic technologies are evolving rapidly. Some people
think that with these new opportunities a deep clinical knowl-
edge becomes outdated. However, the opposite is the case, and
a structured, critically reflected and multi-disciplinary approach
becomes even more important than ever before. Interpretation
of data is now the challenge, and bench and bedside clearly
benefit from smart bioinformatic algorithms and support.
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